Dyne Therapeutics (NASDAQ:DYN) Stock Jumps 5.7% – Should You Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares traded up 5.7% on Monday. The company traded as high as $14.87 and last traded at $15.0670. Approximately 252,044 shares were traded during trading, a decline of 89% from the average daily volume of 2,307,675 shares. The stock had previously closed at $14.25.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DYN. Stifel Nicolaus set a $37.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $17.00 to $10.00 in a research note on Wednesday, September 9th. Cantor Fitzgerald restated a “buy” rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. Finally, Morgan Stanley cut their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.07.

Dyne Therapeutics Trading Up 6.8%

The company’s fifty day simple moving average is $20.06 and its 200-day simple moving average is $20.36. The firm has a market capitalization of $3.04 billion, a PE ratio of -4.89 and a beta of 1.12. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Wednesday, July 29th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other news, Director Brian S. Posner acquired 2,500 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the purchase, the director owned 27,000 shares in the company, valued at approximately $432,000. This represents a 10.20% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John Cox sold 5,658 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the transaction, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at $6,749,732.16. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 2,598,706 shares of company stock valued at $65,432,671. 9.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DYN. IFP Advisors Inc lifted its stake in shares of Dyne Therapeutics by 56.5% in the third quarter. IFP Advisors Inc now owns 5,879 shares of the company’s stock worth $95,000 after buying an additional 2,123 shares in the last quarter. GAMMA Investing LLC boosted its position in Dyne Therapeutics by 63.2% during the third quarter. GAMMA Investing LLC now owns 1,882 shares of the company’s stock worth $30,000 after acquiring an additional 729 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at about $300,000. Nykredit A S purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at about $113,000. Finally, Moore Capital Management LP grew its stake in Dyne Therapeutics by 288.2% during the 2nd quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock valued at $6,792,000 after acquiring an additional 227,029 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.

Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.

Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.